February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
With $137 billion and growing spent on treatment in the US healthcare annually, cancer care delivery poses a significant challenge.
Medicare has initiated several programs in the past decade to encourage value, but questions remain regarding their effectiveness.
Redesigning the Payment Model for Acute Leukemia: Benefits and Challenges of the Episode-of-Care Model
Given the high cost of care for acute leukemia, innovative payment strategies that reward longitudinal care and create economic incentives for data-driven care delivery are needed.
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination.
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology - Multiple Myeloma, Online First
The year 2015 saw an explosion of new drugs approved by the FDA and new indications for drugs already on the market for multiple myeloma. Overall, 4 new drugs from 2 new classes were approved in 2015, changing the standard of care for patients with this disease.
With the recent FDA approval of the first oral proteasome inhibitor ixazomib (Ninlaro), patients with relapsed or refractory multiple myeloma who have received previous treatment now have access to an all-oral regimen.
The immunostimulatory monoclonal antibody elotuzumab (Empliciti), which was approved by the FDA in December 2015, is being studied in combination with immunomodulatory drugs and proteasome inhibitors in patients with relapsed or refractory multiple myeloma.
With the accelerated FDA approval in December 2015 of the anti-CD38 monoclonal antibody daratumumab (Darzalex) for patients with multiple myeloma who received ≥3 previous therapies, studies of the drug presented at ASH 2015 were of great interest.
Immunotherapy is generating great excitement in melanoma and non–small-cell lung cancer (NSCLC).
The use of therapy with chimeric antigen receptor (CAR)-modified T-cells consistently demonstrated activity in advanced hematologic malignancies, including different types of lymphoma, in multiple trials reported at ASH 2015.
Page 1 of 2
Results 1 - 10 of 18
Results 1 - 10 of 18